Yupelri

Drug Overview

What sets Yupelri apart from many other maintenance therapies is its delivery method. Many patients with advanced lung disease struggle to inhale deeply or forcefully enough to use standard handheld inhalers. Yupelri is formulated as a liquid solution designed for a nebulizer, allowing patients to breathe normally while the machine transforms the medication into a fine mist. This ensures the medicine reaches deep into the lungs, providing reliable, 24-hour symptom control.

• Generic Name: Revefenacin
• US Brand Names: Yupelri
• Route of Administration: Nebulization (Inhalation Solution)
• FDA Approval Status: FDA-approved for the maintenance treatment of patients with Chronic Obstructive Pulmonary Disease (COPD).

What Is It and How Does It Work? (Mechanism of Action)

Yupelri (revefenacin) is a long-acting muscarinic antagonist used in COPD. It blocks M3 receptors on airway smooth muscle, preventing acetylcholine-induced bronchoconstriction and promoting relaxation. This maintains open airways for 24 hours. Rapid systemic breakdown limits side effects while prolonged lung receptor binding ensures sustained bronchodilation and improved breathing ease. 

FDA-Approved Clinical Indications

Primary Indication

The primary FDA-approved indication for Yupelri is the Maintenance treatment of COPD. This includes chronic bronchitis and emphysema. It is intended for long-term, once-daily use to keep airways open and prevent symptoms from worsening.

Other Approved & Off-Label Uses

While specifically approved for COPD, medications in the LAMA class are occasionally discussed in other respiratory contexts:

• Asthma: While typically managed with an Inhaled Corticosteroid (ICS) and a long-acting beta-agonist, a LAMA is sometimes used off-label as an add-on therapy for severe, uncontrolled asthma.
• Bronchiectasis: Used off-label to help keep airways open and assist in the clearance of trapped mucus.

Primary Pulmonology Indications:

• Improve Ventilation: By blocking the signals that cause airway narrowing, the drug significantly increases the internal diameter of the bronchial tubes, allowing trapped air to escape and fresh air to enter.
• Reduce Exacerbations: Keeping the airways consistently open prevents the rapid deterioration of lung function (flare-ups) that often lead to emergency room visits and hospitalizations.
• Slow the Decline of Lung Function: Chronic constriction and inflammation damage lung tissue over time. Consistent daily bronchodilation reduces physical stress on the lungs, helping to preserve the patient’s remaining breathing capacity.

Dosage and Administration Protocols

Yupelri is designed strictly for use with a standard jet nebulizer connected to an air compressor. It is important to note the difference between short-acting rescue medications (SABA/SAMA) and long-acting maintenance therapies (LABA/LAMA). Yupelri is a long-acting maintenance therapy and must be used every day, not just when symptoms flare up.

Export to Sheets

Specific Patient Population Adjustments:

• Hepatic Impairment: Yupelri is not recommended for patients with severe liver impairment (severe hepatic impairment), as the drug is processed through the liver. No dosage adjustment is needed for mild to moderate liver issues.
• Renal Impairment: No dosage adjustment is required for patients with kidney disease.
• Elderly Patients: Administered at the standard dose; the nebulized route is particularly beneficial for elderly patients with low inspiratory flow who cannot use dry powder inhalers.

Inhalation Technique Instructions: Empty the entire contents of one vial into the nebulizer cup. Breathe calmly and normally through the mouthpiece until the mist stops (usually about 8 minutes). Because Yupelri is not an Inhaled Corticosteroid (ICS), the risk of oral thrush is very low, but rinsing the mouth and washing the nebulizer mouthpiece with warm, soapy water after use is recommended for overall hygiene.

“Dosage must be individualized by a qualified healthcare professional.”

Clinical Efficacy and Research Results

Current clinical research (2020-2026) reinforces the strong efficacy profile of revefenacin as a once-daily nebulized therapy. In extensive Phase III clinical trials, patients using Yupelri demonstrated significant improvements in respiratory mechanics and daily living metrics compared to those using a placebo.

A primary measure of lung function is FEV1 (Forced Expiratory Volume in one second). Clinical data shows that patients receiving Yupelri achieved a significant improvement in their trough FEV1, with an average increase of 146 mL over baseline. This measurable widening of the airways translates to noticeable relief for the patient.

Furthermore, research utilizing the St. George’s Respiratory Questionnaire (SGRQ)—a tool used to measure quality of life in patients with airway diseases—shows that consistent use of this LAMA reduces shortness of breath during routine activities. Patients also report improvements in their 6-minute walk distance (6MWD), allowing them to engage more actively in pulmonary rehabilitation programs. By maintaining open airways, Yupelri also contributes to a reduction in annual exacerbation rates, keeping vulnerable COPD patients out of the hospital.

Safety Profile and Side Effects

Black Box Warning: There is NO Black Box Warning for Yupelri. It is important to note that the asthma-related death warnings historically associated with certain LABAs do not apply to the LAMA drug class. However, Yupelri is a maintenance medication and should never be used as a rescue inhaler for acute bronchospasm.

Common Side Effects (>10%)

• Cough
• Nasopharyngitis (runny nose and sore throat)
• Upper respiratory tract infection
• Headache
• Back pain

Serious Adverse Events

• Paradoxical Bronchospasm: As with other inhaled medicines, Yupelri can cause life-threatening paradoxical bronchospasm (sudden tightening of the airways immediately after use). If this occurs, treatment must be stopped immediately and a rescue inhaler used.
• Worsening of Narrow-Angle Glaucoma: Because it is an anticholinergic, the mist can increase pressure in the eyes if it escapes the nebulizer mask. Patients should use a mouthpiece rather than a face mask whenever possible to prevent the mist from getting into the eyes.
• Worsening of Urinary Retention: Can cause difficulty passing urine, especially in men with enlarged prostates.

Management Strategies

Patients must always keep a fast-acting rescue inhaler (like albuterol) on hand for sudden breathing problems. To avoid eye complications, a tight seal on the nebulizer mouthpiece is preferred over a face mask. Patients experiencing new or worsening eye pain, blurred vision, or difficulty urinating should contact their physician immediately.

Research Areas

Direct Clinical Connections

Active research between 2020 and 2026 is highly focused on how LAMA medications like Yupelri impact mucociliary clearance. In COPD, excess mucus production is a major problem. Because muscarinic receptors also control mucus gland secretions, blocking these receptors with revefenacin can reduce the overproduction of phlegm, helping patients clear their airways more effectively. Additionally, studies are evaluating its long-term role in slowing airway remodeling, which is the permanent thickening and scarring of the lung tubes.

Generalization and Advancements

The respiratory field is seeing rapid advancements in Novel Delivery Systems. Research is currently evaluating the integration of “Smart” nebulizers equipped with Bluetooth technology. These devices track when a patient takes their Yupelri dose and monitor inhalation patterns, sending real-time data to healthcare providers to ensure maximum drug delivery and adherence.

Severe Disease & Precision Medicine

In the era of precision medicine, pulmonologists rely on “Biologic” phenotyping to tailor treatments. By testing a patient’s blood for specific immune cells (like eosinophils vs. neutrophils), doctors can determine the exact nature of their COPD. Patients with non-eosinophilic (neutrophilic) inflammation often do not respond well to steroids. For these patients, using a potent, nebulized Bronchodilator like Yupelri serves as an ideal Targeted Therapy to manage severe disease without the unnecessary side effects of an Inhaled Corticosteroid (ICS).

Clinical disclaimer

Information about mucociliary clearance, airway remodeling, adherence-monitoring nebulizers, or precision phenotyping should be treated as investigational unless supported by direct clinical evidence. The clearest established role of revefenacin remains bronchodilation for COPD symptom control rather than proven disease modification.

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: Comprehensive Spirometry (PFTs) is required to establish baseline lung function and confirm the COPD diagnosis. Chest X-rays or CT scans may be used to evaluate the extent of emphysema. Baseline oxygen saturation (SpO2) should be recorded via pulse oximetry.
• Organ Function: Because the drug is metabolized by the liver, baseline hepatic function should be assessed to rule out severe hepatic impairment.
• Specialized Testing: While not strictly required for LAMA therapy, checking sputum eosinophil counts can help doctors decide if additional therapies are needed.
• Screening: A thorough review of the patient’s ability to set up, clean, and use a nebulizer machine properly is mandatory.

Monitoring and Precautions

• Vigilance: Patient progress should be monitored using standardized tools like the COPD Assessment Test (CAT). A lack of symptom improvement may indicate a need for a “Step-up” in therapy, such as adding a long-acting beta-agonist (LABA).
• Lifestyle: Smoking cessation is an absolute requirement; continuing to smoke severely diminishes the effectiveness of pulmonary medications. Patients should also participate in daily pulmonary rehabilitation exercises to maintain chest wall muscle strength.
• Vaccination: Patients must remain up to date on annual Flu and Pneumonia vaccinations to prevent severe respiratory infections that can trigger life-threatening COPD exacerbations.

“Do’s and Don’ts” list

• DO use your nebulizer treatment at the same time every day to establish a consistent routine.
• DO clean your nebulizer cup and mouthpiece daily with warm, soapy water to prevent bacterial infections.
• DO keep a fast-acting rescue inhaler with you at all times for sudden shortness of breath.
• DON’T mix Yupelri with other liquid medications in the nebulizer cup unless specifically instructed by your pulmonologist.
• DON’T use this medication to treat a sudden asthma or COPD attack; it works too slowly for emergencies.
• DON’T let the nebulizer mist get into your eyes, especially if you have a history of glaucoma.

Legal Disclaimer

The medical information provided in this guide is for educational and informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the direct advice of your physician, Pulmonologist, or other qualified healthcare provider with any questions you may have regarding a medical condition, treatment plan, or medication. Never disregard professional medical advice or delay in seeking it because of information you have read in this document.